Evogene Correlations
| EVGN Stock | USD 1.04 0.02 1.96% |
The current 90-days correlation between Evogene and Novo Nordisk AS is 0.11 (i.e., Average diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Evogene Correlation With Market
Very good diversification
The correlation between Evogene and DJI is -0.48 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Evogene and DJI in the same portfolio, assuming nothing else is changed.
Moving together with Evogene Stock
| 0.76 | EDIT | Editas Medicine | PairCorr |
| 0.76 | QSI | QuantumSi | PairCorr |
| 0.73 | GNLX | Genelux Common | PairCorr |
| 0.7 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.64 | KRRO | Frequency Therapeutics | PairCorr |
| 0.65 | LYRA | Lyra Therapeutics | PairCorr |
| 0.72 | MBIO | Mustang Bio | PairCorr |
| 0.65 | PROK | ProKidney Corp | PairCorr |
| 0.79 | ACXP | Acurx Pharmaceuticals LLC | PairCorr |
Moving against Evogene Stock
| 0.81 | DSGN | Design Therapeutics | PairCorr |
| 0.64 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.58 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.56 | ENGN | enGene Holdings Common | PairCorr |
| 0.35 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.77 | AVE | Avecho Biotechnology | PairCorr |
| 0.76 | SVRA | Savara Inc | PairCorr |
| 0.75 | ANNX | Annexon | PairCorr |
| 0.6 | SLDB | Solid Biosciences LLC | PairCorr |
| 0.57 | MRKR | Marker Therapeutics | PairCorr |
| 0.49 | BCAX | Bicara Therapeutics | PairCorr |
| 0.38 | BOLT | Bolt Biotherapeutics | PairCorr |
| 0.36 | AVCR | Avricore Health | PairCorr |
| 0.75 | SMFG | Sumitomo Mitsui Financial | PairCorr |
| 0.75 | SMFNF | Sumitomo Mitsui Financial | PairCorr |
| 0.68 | CAPR | Capricor Therapeutics | PairCorr |
| 0.68 | FCAP | First Capital Normal Trading | PairCorr |
Related Correlations Analysis
| -0.43 | 0.62 | 0.51 | 0.54 | GILD | ||
| -0.43 | -0.24 | -0.7 | -0.66 | SNY | ||
| 0.62 | -0.24 | 0.62 | 0.33 | AMGN | ||
| 0.51 | -0.7 | 0.62 | 0.67 | MRK | ||
| 0.54 | -0.66 | 0.33 | 0.67 | NVO | ||
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Evogene Stock performing well and Evogene Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Evogene's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GILD | 1.31 | 0.29 | 0.17 | 1.56 | 1.26 | 3.01 | 6.70 | |||
| SNY | 1.02 | (0.12) | 0.00 | (0.18) | 0.00 | 1.87 | 5.92 | |||
| AMGN | 1.25 | 0.21 | 0.13 | 0.34 | 1.25 | 3.47 | 11.18 | |||
| MRK | 1.30 | 0.43 | 0.30 | 0.61 | 1.09 | 3.59 | 8.09 | |||
| NVO | 2.30 | (0.07) | (0.01) | 0.01 | 3.26 | 5.80 | 13.19 |
Evogene Corporate Management
| Rachel Gerber | Head Relations | Profile | |
| Russ Putland | Executive USA | Profile | |
| Amit res | Chief Ltd | Profile | |
| Dan Gelvan | Chief Ltd | Profile | |
| Dotan Borenstein | Chief Ltd | Profile | |
| Yaron Eldad | Chief Officer | Profile |